The biopharmaceutical sector in early 2026 continues to emphasize innovative drug delivery systems designed to improve patient comfort—a strategic area where Bionxt has established its presence.
The current market nervousness contrasts with IBM's recent operational results. In late January, the company reported fourth-quarter revenue of $19.69 billion, representing an increase of 12.2% ...